MedTrace Logo

Superiority of VCD Versus CTD in Patients With Newly Diagnose Multiple Myeloma Eligible for Transplantation

NCT03402295 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 311

Last updated 2018-01-18

No results posted yet for this study

Summary

This study compared two main different induction protocols used to treat myeloma eligible patients in Brazil. VCD against CTD.

Conditions

Interventions

DRUG

Bortezomib, cyclophosphamide, thalidomide, dexamethasone

Comparison between two triple combination chemotherapy that include in different new drugs (bortezomibe e talidomida)

Sponsors & Collaborators

  • Grupo de Estudos Multicentricos em Onco-Hematologia

    lead NETWORK

Principal Investigators

  • Edvan Cusoe, MD · Federal University of Bahia

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2009-06-15
Primary Completion
2014-06-15
Completion
2017-10-15

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03402295 on ClinicalTrials.gov